FDA's June warning letters treat website claims about compounded GLP-1s as misbranding
Warning letters dated June 8, 2026 cite telehealth websites for calling compounded semaglutide and tirzepatide clinically proven and their compounder FDA licensed. FDA treats the web copy itself as misbranding.
FDA's Office of Compounding Quality and Compliance sent letters to telehealth marketers including OrderlyMeds and AltRx after reviewing their websites in March 2026. Claims such as clinically proven weight loss, and sourcing from an FDA licensed pharmacy, are cited as false or misleading, making the products misbranded under sections 502(a) and 502(bb) and their shipment a violation of section 301(a).
The letters state there is no FDA approved or FDA licensed designation for pharmacies or outsourcing facilities and that registration is not approval. Where a telehealth brand's name appears on the vial without qualification, FDA cites the rule that a name on a label represents the named party as the maker. Recipients have fifteen business days to respond. The letters follow the thirty FDA announced on March 3, 2026, and are allegations, not findings.
- Telehealth companies marketing compounded GLP-1s.
- The 503A and 503B facilities whose products appear under a partner's brand.
- Any pharmacy site describing compounded products as clinically proven or FDA approved.
The letters go to telehealth marketers, but the misbranding provisions they cite apply to the compounder whose product is being described, and FDA notes that labels which name the marketer as if it were the maker are themselves misbranding.
| Source published | June 8, 2026 | Date on the letters. |
|---|---|---|
| Compliance deadline | Not stated | Fifteen business days from receipt to respond. |
These letters are triggered by web copy, not inspections, which makes them the nearest thing to a published rulebook for pharmacy websites: no clinically proven, no FDA approved or FDA licensed, no implying a compounded product was evaluated, and no partner branding that hides who made the drug. The label point reaches the pharmacy, not only the marketer.
- Search your site and your partners' sites for clinically proven, FDA approved, FDA licensed and FDA registered near any compounded product, and fix each instance.
- State plainly that compounded drugs are not FDA approved wherever one is offered.
- Check that every vial label dispensed under a partner arrangement names your pharmacy as the compounder.
Website and Digital Presence. The Website and Digital Presence domain covers the claims a pharmacy's public pages make about products and regulatory status. FDA's cited phrases map directly onto that review.
- Warning letter to OrderlyMeds LLC dba OrderlyMeds, MARCS-CMS 728291 PrimaryFDA Center for Drug Evaluation and ResearchMARCS-CMS 728291Retrieved Sep 21, 2026
March 2026 website review; sections 502(a), 502(bb) and 301(a); the FDA licensed pharmacy claim; footnotes 2 and 3 on labels and on registration not being approval.
- Warning letter to Trinity Healthcare Supply LLC dba AltRx, MARCS-CMS 728236 PrimaryFDA Center for Drug Evaluation and ResearchMARCS-CMS 728236Retrieved Sep 21, 2026
The clinically proven claims and FDA's response that compounded drug products are not FDA approved.
- FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s SecondaryU.S. Food and Drug AdministrationRetrieved Sep 21, 2026
Press announcement of March 3, 2026; context for the continuing program.
Know where your pharmacy stands before the rules change again.
Certified pharmacies are re-verified nightly against state boards, federal enforcement records and their own websites.